BCA
BDTX icon

Berman Capital Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Berman Capital Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-184
Closed -$2K – 2064
2021
Q2 		$2K Buy
+184
New +$3.64K ﹤0.01% 1561

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Berman Capital Advisors's BDTX Position: Q3 2021 in Review

Berman Capital Advisors sold out of Black Diamond Therapeutics (BDTX) in Q3 2021, closing a stake of 184 shares — an estimated $2K sold.

Berman Capital Advisors first reported a position in BDTX in Q2 2021 and held it in 1 quarter. The position peaked at $2K in Q2 2021. 101 funds tracked by Wall St. Rank hold BDTX as of Q3 2021.

  • Berman Capital Advisors reported no remaining Black Diamond Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Berman Capital Advisors sold 184 Black Diamond Therapeutics shares in Q3 2021, an estimated $2K.
  • Berman Capital Advisors first reported a position in Black Diamond Therapeutics in Q2 2021 and held it in 1 quarter.
  • Berman Capital Advisors's Black Diamond Therapeutics position peaked at $2K in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.